Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mayes

Showing results (291-300 of 382) with videos related to

Pageof 39
Sort By:
Arthritis Care & Research|June 27, 2024
Minimal Detectable Changes of the Health Assessment Questionnaire-Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional StudyAfra Alkan, Marie-Eve Carrier, Richard S Henry, et al.
International Journal of Behavioral Medicine|January 18, 2024
Moderators of Loneliness Trajectories in People with Systemic Sclerosis During the COVID-19 Pandemic: A SPIN COVID-19 Cohort Longitudinal StudyChelsea S Rapoport, Alyssa K Choi, Linda Kwakkenbos, et al.
Arthritis and Rheumatism|April 29, 2008
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialPeter A Merkel, Nancy P Silliman, Christopher P Denton, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Rheumatology (Oxford, England)|October 24, 2024
Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2385 SPIN Cohort participantsLinda Kwakkenbos, Brooke Levis, Richard S Henry, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Pageof 39

Showing results (291-300 of 382) with videos related to

Sort By:
Pageof 39
Arthritis Care & Research|June 27, 2024
Minimal Detectable Changes of the Health Assessment Questionnaire-Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional StudyAfra Alkan, Marie-Eve Carrier, Richard S Henry, et al.
International Journal of Behavioral Medicine|January 18, 2024
Moderators of Loneliness Trajectories in People with Systemic Sclerosis During the COVID-19 Pandemic: A SPIN COVID-19 Cohort Longitudinal StudyChelsea S Rapoport, Alyssa K Choi, Linda Kwakkenbos, et al.
Arthritis and Rheumatism|April 29, 2008
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialPeter A Merkel, Nancy P Silliman, Christopher P Denton, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Rheumatology (Oxford, England)|October 24, 2024
Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2385 SPIN Cohort participantsLinda Kwakkenbos, Brooke Levis, Richard S Henry, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Pageof 39